Bisphosphonate induced hypocalcaemia – report of six cases and review of the literature | Zendy

Veronika Kreutle | Zendy; C Blum | Zendy; Christian Meier | Zendy; Michele Assaly Past | Zendy; Beat P. MüllerStich | Zendy; Philipp Schütz | Zendy; Katrin Borm | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Bisphosphonate induced hypocalcaemia – report of six cases and review of the literature

Author(s) -

Veronika Kreutle,

C Blum,

Christian Meier,

Michele Assaly Past,

Beat P. MüllerStich,

Philipp Schütz,

Katrin Borm

Publication year - 2014

Publication title -

schweizerische medizinische wochenschrift

Language(s) - English

Resource type - Journals

ISSN - 0036-7672

DOI - 10.4414/smw.2014.13979

Subject(s) - hypocalcaemia , medicine , denosumab , bisphosphonate , osteoporosis , vitamin d and neurology , bone metastasis , surgery , metastasis , cancer , calcium

Intravenous bisphosphonates are widely used to treat osteoporosis and bone metastasis in cancer patients The risk of hypocalcaemia is a rare but underestimated side effect of anti-resorptive treatment. Clinically apparent hypocalcaemia is mostly related to high-dose treatment with zoledronate and denosumab in cancer patients Particular caution is mandatory in all malnourished patients and patients with renal failure who are treated for either bone metastases or osteoporosis. To avoid serious hypocalcaemia, pre-treatment calcium and vitamin D status should be assessed and corrected if appropriate

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research